MetrioPharm

About:

MetrioPharm is a clinical stage pharmaceutical development company.

Website: https://www.metriopharm.com

Top Investors: Duchenne UK

Description:

MetrioPharm AG is a pharmaceutical development company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. They hope to achieve a healthspan expansion for patients: They want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people. MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.

Total Funding Amount:

$20.3M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Zürich, Zurich, Switzerland

Founded Date:

2017-01-01

Founders:

Ekkehard Brysch, Rudolf Stäger, Wolfgang Brysch

Number of Employees:

11-50

Last Funding Date:

2022-10-12

IPO Status:

Private

Industries:

© 2025 bioDAO.ai